You are not logged in.

An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.

Chen, Xiao-Wu, He, Zhi-Xu, Zhou, Zhi-Wei, Yang, Tianxin, Zhang, Xueji, Yang, Yin-Xue, Duan, Wei and Zhou, Shu-Feng 2015, An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus., Clinical and experimental pharmacology and physiology, vol. 42, no. 12, pp. 1225-1238, doi: 10.1111/1440-1681.12469.

Attached Files
Name Description MIMEType Size Downloads

Title An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Author(s) Chen, Xiao-Wu
He, Zhi-Xu
Zhou, Zhi-Wei
Yang, Tianxin
Zhang, Xueji
Yang, Yin-Xue
Duan, Wei
Zhou, Shu-Feng
Journal name Clinical and experimental pharmacology and physiology
Volume number 42
Issue number 12
Start page 1225
End page 1238
Total pages 14
Publisher Wiley
Place of publication London, Eng.
Publication date 2015-12
ISSN 1440-1681
Keyword(s) DPP-4 inhibitor
adverse effect
alogliptin
combination therapy
pharmacokinetics
type 2 diabetes (T2DM)
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Physiology
GLUCAGON-LIKE PEPTIDE-1
INCRETIN-BASED THERAPIES
LONG-TERM EXTENSION
INITIAL COMBINATION THERAPY
INADEQUATE GLYCEMIC CONTROL
PLACEBO-CONTROLLED TRIAL
DRUG-NAIVE PATIENTS
BETA-CELL FUNCTION
DOUBLE-BLIND
JAPANESE PATIENTS
Summary Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that is a class of relatively new oral hypoglycaemic drugs used in patients with type 2 diabetes (T2DM), can be used as monotherapy or in combination with other anti-diabetic agents, including metformin, pioglitazone, sulfonylureas and insulin with a considerable therapeutic effect. Alogliptin exhibits favorable pharmacokinetic and pharmacodynamic profiles in humans. Alogliptin is mainly metabolized by cytochrome P450 (CYP2D6) and CYP3A4. Dose reduction is recommended for patients with moderate or worse renal impairment. Side effects of alogliptin include nasopharyngitis, upper-respiratory tract infections and headache. Hypoglycaemia is seen in about 1.5% of the T2DM patients. Rare but severe adverse reactions such as acute pancreatitis, serious hypersensitivity including anaphylaxis, angioedema and severe cutaneous reactions such as Stevens-Johnson syndrome have been reported from post-marketing monitoring. Pharmacokinetic interactions have not been observed between alogliptin and other drugs including glyburide, metformin, pioglitazone, insulin and warfarin. The present review aimed to update the clinical information on pharmacodynamics, pharmacokinetics, adverse effects and drug interactions, and to discuss the future directions of alogliptin.
Language eng
DOI 10.1111/1440-1681.12469
Field of Research 111502 Clinical Pharmacology and Therapeutics
0606 Physiology
1115 Pharmacology And Pharmaceutical Sciences
1116 Medical Physiology
Socio Economic Objective 920104 Diabetes
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Wiley
Persistent URL http://hdl.handle.net/10536/DRO/DU:30080598

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in TR Web of Science
Scopus Citation Count Cited 4 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 74 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 20 Jul 2016, 11:21:18 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.